Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Primary CNS lymphoma, drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Most patients are over 65 and cannot tolerate curative-intent therapy.
Neurocognitive decline from disease and therapy.
No randomised evidence for maintenance strategies.
Vitreoretinal lymphoma relapse and CNS spread.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
Three-year progression-free survival 78 percent after high-dose chemotherapy and autologous transplant against 51 percent after non-myeloablative R-DeVIC (hazard ratio 0.
A milestone in how this cancer is treated.
IELSG32 second randomisation and PRECIS.
A milestone in how this cancer is treated.
Complete remission 49 percent with MATRix (methotrexate, cytarabine, thiotepa, rituximab) against 23 percent with methotrexate-cytarabine alone; two-year failure-free survival 76 percent after whole-brain radiotherapy and 75 percent after autologous transplant.